

Genesys Diagnostics, Inc. • 8 Enterprise Lane • Phone: (860) 574-9172 • Fax: (860) 574-9264 • Web: www.gdilabs.com • CLIA #: 07D2046796 • Laboratory Director: Dr. Frank Bauer

Patient: Testing, Patient Date of Birth: May 26, 2021 Sex: Male Physician: Frank Bauer NPI #:1851416739 Practice: Genesys Oakdale, CT Phone: 8605749172 Date Collected: Jun 17, 2021 Date Received: Jun 17, 2021 Specimen type/Source: Urine Sample ID: 21055192

### 1. About This Report

This UTI Assay is a urinary tract infection screen that consists of clinical, molecular tests for microorganisms implicated in UTIs.

### 2. Molecular Diagnostic Results

U	ГІ		
-	-	A. baumannii	Negative
-	-	C. albicans	Negative
+	L	C. freundii	Positive
-	-	E. aerogenes	Negative
-	-	E. cloacae	Negative
+	Μ	E. coli	Positive
+	Н	E. faecalis	Positive
+	Н	E. faecium	Positive
-	-	K. oxytoca	Negative
+	Н	K. pneumoniae	Positive
-	-	M. morganii	Negative
-	-	P. aeruginosa	Negative
-	-	P. mirabilis	Negative
-	-	P. stuartii	Negative
-	-	P. vulgaris	Negative
-	-	S. agalactiae	Negative
-	-	S. saprophyticus	Negative
-			

### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 1 of 6



Res	istar	nce Markers	
-	-	ACC	Negative
-	-	ACT/MIR	Negative
-	-	ampC	Negative
-	-	blaIMP	Negative
-	-	CTX-M group 1	Negative
-	-	CTX-M group 8/25	Negative
-	-	CTX-M group 9	Negative
-	-	DfrA1	Negative
-	-	DfrA5	Negative
-	-	ErmA	Negative
-	-	ErmB	Negative
+	М	ErmC	Positive
+	L	fosA	Positive
-	-	FOX	Negative
-	-	gyrA D87N	Negative
-	-	gyrA S83L	Negative
-	-	IMP-2 group	Negative
-	-	КРС	Negative
-	-	mecA	Negative
-	-	NDM	Negative
-	-	OXA-48	Negative
-	-	QnrA	Negative
-	-	QnrS	Negative
ł	Н	SHV	Positive
F	L	sul 1	Positive
•	-	sul 2	Negative
ł	М	TEM	Positive
	-	TEM E102K	Negative
	-	TEM E237K	Negative
-	-	TEM G238S	Negative
-	-	TEM R162S	Negative
ł	М	TetB	Positive
+	М	tetM	Positive
-	-	vanA	Negative
-	-	vanB	Negative
-	-	VIM	Negative

### 3. Antibiotic Treatment Options

The following table shows common treatment options for organisms assayed as present in this sample, combined with any positive or negative assayed resistance markers. "T" indicates a treatment option; "T:R" indicates a treatment option that may be affected by the detected resistance marker(s).

### **CFU** equivalents

Low (L): ≤ 10^4 | Medium (M): 10^4 to 10^6 | High (H): ≥ 10^6 CFU

### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 2 of 6



		undi		alis	2 ciur	n pneumoniae Resistances
	C	.freundi		foecolis	foeciur	. Pher Resistu
Abundance	L	М	Н	Н	Η	
aztreonam (Beta-Lactam)	Т	Т	-	-	-	Negative
fosfomycin		-			Ŧ	
(Broad-spectrum antibiotic)	-	Т	-	-	Т	Not assayed
meropenem (Carbapenem)	Т	Т	-	-	-	Negative
doripenem					-	
(Carbapenem)	Т	-	-	-	Т	Negative
ertapenem (Carbapenem)	-	т	-	-	т	Negative
imipenem						
(Carbapenem)	Т	Т	-	-	-	Negative
ceftazidime/avibactam	-	т	-	-	т	Negative
(Cephalosporin + beta lactamase inhibitors) cefuroxime						
(Cephalosporins)	-	Т	-	-	-	Negative
cefdinir	_	т	_		-	Negative
(Cephalosporins) cefazolin						U
(Cephalosporins)	-	Т	-	-	-	Negative
cefepime	т	Т	-	_	-	Negative
(Cephalosporins) cefotaxime						. toguine
(Cephalosporins)	-	Т	-	-	-	Negative
cefixime		Т	_		_	Negative
(Cephalosporins)						Negative
ceftazidime (Cephalosporins)	-	Т	-	-	-	Negative
cefpodoxime		т				Negative
(Cephalosporins)			-	-	-	negative
ceftriaxone (Cephalosporins)	-	Т	-	-	-	Negative
† amoxicillin			T.D	T.D		TEM
(Extended-Spectrum-Beta lactam)	-	-	T:R	T:R	-	SHV
† piperacillin/tazobactam (Extended-Spectrum-Beta lactam)	T:R	T:R	-	-	-	TEM SHV
† amoxicillin-clavulanate						TEM
Extended-Spectrum-Beta lactam)	-	T:R	-	-	-	SHV
† ampicillin (Extended-Spectrum-Beta lactam)	-	T:R	T:R	T:R	-	
						SHV

### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 3 of 6



. .e

		freundi		faecalis	foeciur	n neunoniae Resistances
Abundance		بر M	،ٽ ج H		,,\' \ H	~Y 80 <sup>3</sup> /
† pivmecillinam (Extended-Spectrum-Beta lactam)	-	T:R	-	-	-	TEM SHV
televancin (Glycopeptides)	-	-	Т	Т	-	Not assayed
tobramycin (Glycoside)	-	т	-	-	-	Not assayed
gentamicin (Glycoside)	т	т	т	-	-	Not assayed
amikacin (Kanamycin)	-	т	-	-	-	Not assayed
penicillin g (Narrow-Spectrum-Beta lactam)	-	-	Т	Т	-	Negative
nitrofurantoin (Nitrofurans)	-	т	т	Т	т	Not assayed
† ampicillin/sulbactam (Penicillin + beta lactamase inhibitors)	-	T:R	-	-	-	TEM SHV
† ampicillin + ceftriaxone (Penicillin + cephalosporin)	-	-	T:R	C	-	TEM SHV
colistin (Peptide)	-	-	-	-	Т	Not assayed
trimethoprim (Pyrimidines)	-	Т	-	-	т	Not assayed
levofloxacin (Quinolone and fluoroquinolone)	-	Т	-	-	Т	Negative
ciprofloxacin (Quinolone and fluoroquinolone)	Т	Т	-	-	т	Negative
† sulfamethoxazole/trimethoprim (Sulfonamides)	T:R	T:R	-	-	-	sul 1
† tigecycline (Tetracyclines)	-	T:R	-	-	T:R	tetM
vancomycin (Vancomycin)	-	-	Т	Т	-	Negative

† Consider alternate treatment due to detected resistance marker(s).

### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 4 of 6



### 4. Microorganisms Tested by Genesys Diagnostics, Inc.

Organism/Assay	Ct Mean	Presence	Organism/Assay	Ct Mean	Presence
A. baumannii		Not Detected	M. morganii		Not Detected
ACC		Not Detected	mecA	30.249	Not Detected
ACT/MIR		Not Detected	NDM		Not Detected
ampC		Not Detected	OXA-48		Not Detected
blaIMP		Not Detected	P. aeruginosa		Not Detected
C. albicans		Not Detected	P. mirabilis		Not Detected
C. freundii	29.584	Detected	P. stuartii		Not Detected
CTX-M group 1		Not Detected	P. vulgaris		Not Detected
CTX-M group 8/25		Not Detected	QnrA		Not Detected
CTX-M group 9		Not Detected	QnrS		Not Detected
DfrA1		Not Detected	S. agalactiae		Not Detected
DfrA5		Not Detected	S. saprophyticus		Not Detected
E. aerogenes		Not Detected	SHV	13.412	Detected
E. cloacae		Not Detected	(Extended-Spectrum-Betalactamase)		
E. coli	24.226	Detected	sul 1	28.594	Detected
E. faecalis	14.306	Detected	(Sulfonamide 1 resistance (sul 1))		
E. faecium	19.344	Detected	sul 2		Not Detected
ErmA		Not Detected	TEM	23.783	Detected
ErmB		Not Detected	(Extended-Spectrum-Betalactamase)		
ErmC	24.317	Detected	TEM E102K		Not Detected
(Erythromycin resistance (ErmC))			TEM E237K		Not Detected
fosA	28.646	Detected	TEM G238S		Not Detected
(fosA)			TEM R162S	00.000	Not Detected
FOX		Not Detected	TetB	22.898	Detected
gyrA D87N		Not Detected	(Tetraycline Resistance (TetB)) tetM	24 452	Detected
gyrA S83L		Not Detected	(tetracycline-resistant ribosomal	24.032	Delected
IMP-2 group		Not Detected	protection protein)		
K. oxytoca		Not Detected	vanA		Not Detected
K. pneumoniae	13.734	Detected	vanB		Not Detected
KPC		Not Detected	VIM		Not Detected

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The UTI Diagnostic Report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.

Methodology: Array based assays simultaneously detect a wide array of bacteria, viruses, and parasites at analytical sensitivity and specificity >99%.

Disclaimer: These tests were developed and characterized by Genesys Diagnostics, Inc. and interpreted by Coriell Life Sciences, 4747 South Broad Street, Building 101, Suite 222, Philadelphia, PA 19112. The tests in this UTI panel have not been approved by the Food and Drug Administration. The FDA has determined that such approval is not necessary, provided that the laboratory both (1) maintains its good standing as a clinical testing laboratory with all mandatory accrediting bodies, and (2) continually demonstrates that its testing protocols and procedures achieve a high degree of analytical accuracy.

#### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 5 of 6





Laboratory Certification: CLIA # 07D2046796

Laboratory Director: Dr. Frank Bauer

#### 21055192 - Testing, Patient - Reported Jul 01, 2021

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2021, Coriell Life Sciences Inc.



Pg. 6 of 6